Cristescu et al. (44) revealed that TMB and inflammatory biomarkers (T cell–inflamed gene expression profile and PD-L1 expression) could jointly predict clinical response to pembrolizumab in a wide range of tumor types. Here, CD274 is linked to neoplasm.